Pediatric Endocrinologist (Child Hormone Specialist)
Dr. Haller's research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.
This is a randomized, parallel group, double-blind Phase 2 study with a 52-week blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin鈥�
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to鈥�
145 publications
2024
The Joint Commission Journal on Quality and Patient Safety
2024
BMJ Open Diabetes Research & Care
2024
Diabetes Care
2024
Frontiers in endocrinology
鈥�2024
CPT: Pharmacometrics & Systems Pharmacology